Clinical Trials
49 trialsA Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
National Cancer Institute (NCI)
METZOLIMOS
Institut Bergonié
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
Children's National Research Institute
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Emory University
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
National Institutes of Health Clinical Center (CC)
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
ASCR
Washington University School of Medicine
AflacST1501
Emory University
NAC to Prevent Cisplatin-induced Hearing Loss
Children's Hospital Los Angeles
Cabozantinib With Topotecan-Cyclophosphamide
Dana-Farber Cancer Institute
LVPK
BTG International Inc.
Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
MacroGenics
Aflac ST0901
Emory University
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
AflacST1402
Emory University
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
Nationwide Children's Hospital
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma
St. Jude Children's Research Hospital
Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma
University of Louisville
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients
SillaJen, Inc.
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Rutgers, The State University of New Jersey
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
City of Hope Medical Center
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
National Cancer Institute (NCI)
Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Children's National Research Institute
Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors
Children's Oncology Group
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
Children's Oncology Group
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
Children's Oncology Group
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
High-Dose Methotrexate in Treating Young Patients With Solid Tumors
National Cancer Institute (NCI)
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
National Cancer Institute (NCI)
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
National Cancer Institute (NCI)
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
Memorial Sloan Kettering Cancer Center
Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent Osteosarcoma
Memorial Sloan Kettering Cancer Center
ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors
St. Jude Children's Research Hospital
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
National Institutes of Health Clinical Center (CC)
ABT-751 in Treating Young Patients With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
National Institutes of Health Clinical Center (CC)
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center
A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors
National Institutes of Health Clinical Center (CC)
A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma
National Institutes of Health Clinical Center (CC)